BOBBI OTTIS: Open Payments
NPI 1316318421 · NORFOLK, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,019 in 56 payments from 11 companies in 2025. Trend: 2023 $185 · 2024 $593 · 2025 $1,019
Food & beverage: $1,019
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $215 |
| Vanda Pharmaceuticals Inc. | 8 | $176 |
| Otsuka America Pharmaceutical, Inc. | 10 | $162 |
| Teva Pharmaceuticals USA, Inc. | 4 | $104 |
| Neurocrine BioSciences, Inc. | 3 | $94 |
| E.R. Squibb & Sons, L.L.C. | 4 | $89 |
| Corium, LLC | 2 | $54 |
| Supernus Pharmaceuticals, Inc. | 2 | $44 |
| Janssen Pharmaceuticals, Inc | 2 | $37 |
| Alkermes, Inc. | 1 | $22 |
Products named: VRAYLAR, HETLIOZ, REXULTI, INGREZZA, COBENFY, ABILIFY MAINTENA, Azstarys, AUSTEDO XR.
Industry payments across NE — which companies pay providers there.
